ALLR · Allarity Therapeutics, Inc. · Insider Trading

Restricted stock units convert into common stock on a one-for-one basis.

On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date.

The amount reported in column 9 reflects 175,283 restricted stock units outstanding following the January 22, 2026 settlement, plus 133,333 restricted stock units granted on January 28, 2026 and previously reported, less 39,494 restricted stock units settled on September 30, 2026.

Restricted stock units convert into common stock on a one-for-one basis.

Represents shares withheld by the Issuer to satisfy tax withholding obligations arising upon the vesting and settlement of restricted stock units. The shares were withheld based on the fair market value of the Issuer's common stock on the applicable vesting date.

The 381,644 amount previously reported in column 5 of Table I of the Reporting Person's Form 4/A filed April 30, 2026 combined issued shares of common stock and unvested restricted stock units and did not reflect the 17,814 shares withheld on January 22, 2026. This Form 4 reports issued shares of common stock in Table I and unvested restricted stock units separately in Table II. After giving effect to the January 22, 2026 vesting and withholding and the January 28, 2026 restricted stock unit grant, the correct balances were 55,214 shares of common stock and 308,616 restricted stock units.

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date.

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

Restricted stock units convert into common stock on a one-for-one basis.

On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date.

Restricted stock units convert into common stock on a one-for-one basis.

Represents shares withheld by the Issuer to satisfy tax withholding obligations arising upon the vesting and settlement of restricted stock units. The shares were withheld based on the fair market value of the Issuer's common stock on the applicable vesting date.

The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, vested in full on the grant date.

Restricted stock units convert into common stock on a one-for-one basis.

Restricted stock units convert into common stock on a one-for-one basis.

On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date.

The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversary of the grant and are exercisable beginning as of that date.

The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversay of the grant and are exercisable beginning as of that date.

The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the anniversary of the grant and are exercisable beginning as of that date.

The restricted stock units, or RSUs, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The restricted stock units, or RSUs, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The restricted stock units, or RSUs, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

The Reporting Person was granted 118,483 restricted stock units, or RSUs, in connection with the Reporting Person's appointment as President and Chief Development Officer of the Issuer. The RSUs will vest in equal one-third installments on the first, second, and third anniversary of the Reporting Person's appointment, subject to the Reporting Person's continued relationship with the Issuer through each such date.